Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

By A. Karnoub, Ajeeta B. Dash, A. P. Vo, A. Sullivan, M. Brooks, George W. Bell, A. Richardson, K. Polyak, R. Tubo, R. Weinberg. Nature, 2007

3,177 citations recorded by the source corpus.

Subfields: Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/4590cfcf3aa962d1b217bf578ccba385d9d62ce6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. R. Weinberg
2. M. Nieto
3. J. P. Thiery
4. Raghu Kalluri
5. J. Massagué
6. D. Hanahan
7. S. Morrison
8. K. Polyak

In Oncology

1. R. Weinberg
2. D. Hanahan
3. Lisa M. Coussens
4. J. Massagué
5. M. Nieto
6. Raghu Kalluri
7. J. Pollard
8. J. Joyce

Citations in the corpus

• Biomechanical remodeling of the microenvironment by stromal Caveolin-1 favors tumor invasion and metastasis (2011, methodology): “CAFs, the main cell component of the desmoplastic stroma of solid cancers and their metastases (Bhowmick et al., 2004), influence TC growth through paracrine secretion of growth factors and recruit endothelial progenitors to promote angiogenesis (Karnoub et al., 2007; Orimo et al., 2005).”
• Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. (2008, background): “Beyond affecting tumor growth, normal cells can also regulate metastasis: for example, mesenchymal cells in or around tumors can increase the metastasis of breast cancer cells (Karnoub et al., 2007).”
• Hallmarks of cancer: the next generation. (2011, positive): “For example, mesenchymal stem cells (MSCs) present in the tumor stroma have been found to secrete CCL5/RANTES in response to signals released by cancer cells; CCL5 then acts reciprocally on the cancer cells to stimulate invasive behavior (Karnoub et al., 2007).”
• Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression (2009, neutral): “[33].”
• Risk factors in the development of stem cell therapy (2011, background): “the bone marrow, muscle, or spleen, particularly when the tissues are damaged or under pathological conditions such as ischemia or cancer [32,81,82,84,85].”
• Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC (2011, background): “Indeed, previous work has demonstrated that although MSC themselves do not develop teratoma even when derived from a teratoma-forming human embryonic stem cell line [141], a close vicinity to neoplastic breast epithelial cells within the tissue microenvironment can stimulate growth and metastasis of”
• Intratumor heterogeneity: the Rosetta stone of therapy resistance (2020, background): “, 2017) or interaction with stromal cells (Karnoub et al., 2007).”
• Genetics and biology of prostate cancer (2018, background): “For example, MSCs can promote metastasis of breast, gastric, and prostate cancers (Karnoub et al. 2007; Quante et al. 2011; Jung et al. 2013).”